EVOHair

EVOHair: Regenerative Cell Therapy for Hair Growth

 EVOHair introduces a novel regenerative approach to hair restoration by leveraging the unique biological properties of senescent cells. Recent studies demonstrate that senescent cells play an active role in stimulating hair follicle regeneration and enhancing wound healing, offering a transformative new mechanism for treating hair loss.

Unmet Need

Alopecia affects nearly 20% of the global population. Androgenic Alopecia (AGA) accounts for over 90% of all hair loss cases. Only two approved treatments exist (minoxidil and finasteride), both with limited efficacy and side effects. There is a clear need for biologically based, durable solutions that address the underlying regenerative deficit.

Our Technology

 Building on EVOCellic’s proprietary cell technology, EVOHair utilizes senescent cell formulations covered by existing intellectual property to activate dormant hair follicles and restore natural hair growth. The approach combines scientific validation with translational feasibility for both medical and cosmetic applications.

Development Stage

 Pre-clinical phase focused on optimizing senescent cell production and formulation. Early research supports hair follicle activation and dermal regeneration potential. Roadmap includes in vitro and ex vivo efficacy studies, followed by first-in-human trials.

Investment Opportunity

 EVOHair offers a first-in-class therapeutic platform targeting a massive global market estimated at $10B annually. We are seeking a strategic partner or investor to co-develop and advance this breakthrough in regenerative dermatology, with potential applications in both medical and aesthetic markets.